{"id":"clobex-lotion","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypertrichosis"},{"rate":null,"effect":"Acneiform eruptions"},{"rate":null,"effect":"Hypopigmentation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating glucocorticoid receptors in skin cells, leading to decreased production of inflammatory mediators, reduced vasodilation, and suppression of immune cell infiltration. This results in rapid reduction of inflammation, itching, and other dermatological symptoms associated with various skin conditions.","oneSentence":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:13.448Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses"},{"name":"Psoriasis"},{"name":"Lichen planus"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT06363539","phase":"PHASE2","title":"Silver Nitrate Versus Topical Steroid For Umbilical Granuloma","status":"COMPLETED","sponsor":"Children Hospital and Institute of Child Health, Lahore","startDate":"2022-09-20","conditions":"Umbilical Granuloma","enrollment":354},{"nctId":"NCT06042647","phase":"PHASE4","title":"Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-07-13","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT03779360","phase":"NA","title":"Intradermal LPS and Antibiotics","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-10-12","conditions":"Inflammation; Skin","enrollment":32},{"nctId":"NCT00438399","phase":"PHASE3","title":"Subject Preference for Scalp Psoriasis Treatment","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-02","conditions":"Scalp Psoriasis","enrollment":219},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT00864500","phase":"PHASE1","title":"Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-11","conditions":"Healthy","enrollment":224},{"nctId":"NCT00864240","phase":"PHASE1","title":"The Dose-response \"Pilot\" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-10","conditions":"Healthy","enrollment":15},{"nctId":"NCT00852761","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-03","conditions":"Plaque-Type Psoriasis","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":88,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["clobetasol lotion","Clobex"],"phase":"marketed","status":"active","brandName":"Clobex lotion","genericName":"Clobex lotion","companyName":"Stiefel, a GSK Company","companyId":"stiefel-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Lichen planus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}